Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.

NCT02176122 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.

NCT NCT02176122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02176122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Lead sponsor
The University of Queensland
Phase
Phase 4
Overall status
Terminated
Start date
February 28, 2014
Completion date
August 7, 2017
Enrollment
391 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

bloodstream infections